The development of clinically useful histone deacetylase inhibitors has expanded greatly. In a preclinical study, we showed that panobinostat (LBH589) inhibits cell cycle progression of human head and neck squamous cell carcinoma (HNSCC) cell lines at G 2 /M and an associated decrease in expression of particular genes required for passage through G 2 and mitosis. In this study we sought to analyse the mechanistic underpinnings of panobinostat-induced growth arrest. HNSCC cell lines were synchronised and progression through mitosis monitored. We demonstrate that panobinostat causes a marked G 2 delay and mitotic defects. A loss of G 2 -specific Plk1 and Cyclin B1 expression and co-incident increase in p21 Waf1/Cip1 expression is also shown. Furthermore, we show a significant loss of E2F1 recruitment to the promoters of these genes in response to panobinostat treatment. These data provide mechanistic evidence of panobinostat-induced cell cycle arrest and highlight its potential as a chemotherapeutic agent for HNSCC.
The development of clinically useful histone deacetylase inhibitors has expanded greatly. In a preclinical study, we showed that panobinostat (LBH589) inhibits cell cycle progression of human head and neck squamous cell carcinoma (HNSCC) cell lines at G 2 /M and an associated decrease in expression of particular genes required for passage through G 2 and mitosis. In this study we sought to analyse the mechanistic underpinnings of panobinostat-induced growth arrest. HNSCC cell lines were synchronised and progression through mitosis monitored. We demonstrate that panobinostat causes a marked G 2 delay and mitotic defects. A loss of G 2 -specific Plk1 and Cyclin B1 expression and co-incident increase in p21 Waf1/Cip1 expression is also shown. Furthermore, we show a significant loss of E2F1 recruitment to the promoters of these genes in response to panobinostat treatment. These data provide mechanistic evidence of panobinostat-induced cell cycle arrest and highlight its potential as a chemotherapeutic agent for HNSCC.
S quamous cell carcinoma of the head and neck (HNSCC) is a disease of considerable morbidity and mortality with an estimated 560,000 cases per year and 300,000 deaths worldwide, and approximately 50,000 new cases and 11,000 deaths in the United States annually 1, 2 . HNSCC occur in the upper aerodigestive tract from the nasopharynx and oral cavity to the larynx with varying metastatic rates for each anatomic site. Treatment depends upon the disease location, the extent of the primary tumour and the presence of metastatic disease. Conventional treatment usually includes surgery and adjuvant radiation therapy, with or without chemotherapy. Any of these therapies can, and do, produce morbidities affecting speech, swallowing and overall quality of life. Despite these interventions, recurrence of the disease is observed in about 50% of patients with high rates of associated mortality 3 . Even though there has been only a modest improvement in overall survival over the past decades, it has been questioned whether a large percentage of patients are over-treated, incurring additional morbidity 2 . Therefore, strategies must be developed for the most appropriate treatment for any given patient and new treatment paradigms need to be defined.
Histone deacetylases (HDACs) are a group of enzymes that remove acetyl groups from histone proteins, thereby compacting chromatin and silencing the expression of genes. There are now 18 known HDACs grouped into four classes, which can also deacetylate numerous non-histone target proteins and alter their function. Indeed, some HDACs have been shown to alter the transcriptional activity of proteins such as p53, E2F and cMyc [4] [5] [6] . HDAC inhibition is generally thought to increase the expression of repressed genes, including tumor suppressor genes, causing dramatic effects on cell growth and survival and because of this normal cells may be ten-fold or more resistant to HDAC inhibitor (HDACi) induced cell death than transformed cells Panobinostat has been shown to be effective in the treatment of hematologic malignancies such as Hodgkin lymphoma, multiple myeloma and cutaneous T-cell lymphoma [8] [9] [10] [11] [12] and its use has also been tested for the treatment of epithelial neoplasms either alone or in combination with other chemotherapeutic agents [13] [14] [15] [16] [17] [18] [19] . While these are very early clinical trials, some of the initial results are promising. In a preclinical study, we showed that panobinostat inhibits cell cycle progression of human HNSCC cell lines ultimately resulting in cell death in vitro 20 . The cell cycle arrest occurred at G 2 /M and has been observed in other studies using a variety of cell types including the prostate cancer cell lines, PC3 and PC9 and an epithelial lung cancer cell line A549 21, 22 . In our study, we showed that the G 2 /M arrest was associated with a substantial decrease in the expression of a particular sub-set of genes that are required for the passage through the G 2 checkpoint and into mitosis 20 . The objectives of the present study were to define more specifically the cell cycle arrest caused by panobinostat and to elucidate the mechanistic underpinnings.
Results
Previously we showed that panobinostat results in a significant arrest of the cells at G 2 /M within 12 h post treatment 20 . To characterise this arrest further and study potential defects in DNA replication, cells were synchronised by double thymidine block and released into medium containing 100 nM panobinostat or excipient control. At 0 h, cells are synchronised at the G 1 /S boundary (figure 1A). Control treated cells progressed into S phase 4 h post release and passaged through G 2 /M and into G 1 phase by 8 h. By 12 h, the majority of the cells had passed through mitosis and entered G 1 phase. Cells subsequently re-entered S phase (20.5 h), showing completion of one cell cycle. Cells released into 100 nM panobinostat entered and passed through S phase with similar kinetics as the control cell population, but in contrast to control cells, displayed a significant and prolonged G 2 /M arrest at 8 and 12 h post release ( figure 1A and B) . By 20.5 h, some cells remained arrested at G 2 /M but entry into G 1 phase was apparent, suggesting that treatment with panobinostat induces a prolonged cell cycle delay, but not a complete arrest. Similar effects of panobinostat on cell cycle progression were observed in UMSCC-1 and UMSCC-47 cells (oral cavity, obtained from Dr. Thomas Carey, University of Michigan 23 ), with a significant increase in G2/ M cells 11.5 hours post release into medium containing 100 nM panobinostat compared to cells released into control medium (11.5% (p 5 0.02) and 21.7% (p 5 0.0006) increase in the G2/M fraction in UM-SCC-1 and UMSCC-47 cells, respectively). To support the notion that this increase is due to a G2 arrest, a significant decrease in G 1 entry was also observed with this experiment (12.4% (p 5 0.009) and 19.1% (p 5 0.01) decrease in G 1 fraction on UMSCC-1 and UMSCC-47 cells, respectively). These data provide evidence that the cell cycle arrest caused by panobinostat treatment is not cell type specific (supplementary figure 1) .
To determine whether the cells were delayed at G 2 phase or in mitosis, phosphorylation of histone H3 (Serine 10) was assessed ( figure 1C ). Histone H3 phosphorylation in control treated cells peaked at around 9% at 9 h and quickly fell to below 3% by 12 h, indicating mitotic entry and exit between 8 and 12 h post release ( figure 1D ). In contrast, panobinostat-treated cells displayed a delay in mitotic entry, reaching a peak of only 4.5% phosphorylated histone H3 at 12 h, 4 h later than the control population. This strongly suggests that panobinostat results in a significant delay at G 2 phase and reduced mitotic entry.
To confirm these data, we prepared metaphase spreads of synchronised cells at various times post release ( figure 2A ). The number of metaphases present in the control population peaked at 9 h (11.5%) while cells cultured in 100 nM panobinostat showed a highly significant reduction in metaphase cells (p , 0.0001), confirming the reduced mitotic entry observed by histone H3 phosphorylation. Although there is reduced entry into mitosis in cells treated with panobinostat, some cells clearly enter mitosis. We therefore sought to determine whether mitosis progressed normally in panobinostattreated cells. Synchronised cells were fixed 9 h post release, and the mitotic spindles and DNA stained (figure 2B). The results confirmed reduced mitotic entry ( Figure 2C ; 10% compared to 20% in controltreated cells, p , 0.01). In addition, the percentage of the total mitotic cells in pre-anaphase (prophase and metaphase) was significantly increased by nearly three fold following panobinostat treatment (figure 2D; 87.5% compared to 32% in control cells, p , 0.002), with a concomitant decrease in the percentage of mitotic cells in late stage mitosis (anaphase and telophase, p , 0.001). Many mitotic cells at metaphase had non-aligned chromosomes, where cells had appeared to form a normal bipolar spindle but the chromosomes had not congressed to the metaphase plate (3.5% in control cells compared to 46% in panobinostat treated cells p , 0.001). In the few cells that were found to have progressed into anaphase, many had lagging chromosomes (12.5%, compared to 0% in control cells) although this was not statistically significant (p 5 0.2), likely because very few cells are able to progress into anaphase.
To visualize the G 2 delay and mitotic failure, we imaged live cells by timelapse microscopy to observe the progression of panobinostat treated cells into and through mitosis (figure 3 and supplementary movies 1 and 2). While synchronised control cells entered mitosis 8-9 h post release and cells successfully completed mitosis within 1-2 h, panobinostat-treated cells had far fewer successful mitoses (one indicated by arrow (a) in the field), and some cells appeared to enter mitosis (arrow (b)) but remain rounded, for over 10 h in this case, and failed to complete mitosis.
Our previous report showed that panobinostat causes a dramatic reduction in genes required for cell cycle progression including Pololike kinase 1 (PLK1) 20 . We therefore hypothesised that the mitotic abnormalities observed are due to a loss of cell cycle dependent Plk1 expression. To test this, RNA and protein were prepared from synchronised cells cultured in the presence or absence of panobinostat for 2, 4, 8 and 12 h post release. Plk1 mRNA and protein expression dramatically increased by 8 h post release in control cells, however no significant increase in PLK1 mRNA or protein was observed in panobinostat-treated cells (figure 4). In addition, microarray analysis of gene expression in synchronised FaDu cells released for 8 h in panobinostat or excipient control revealed a significant reduction in the expression of Cyclin B1 mRNA (data not shown). More careful analysis of Cyclin B1 mRNA and protein expression showed an increase in expression between 4 and 8 h post release in control cells, concomitant with mitotic entry, but a loss of cell cycle dependent upregulation in panobinostat-treated cells (figure 5). The loss of cell cycle dependent upregulation of Plk1 and Cyclin B1 protein expression was also assessed in two further oropharyngeal squamous cell carcinoma cell lines (UMSCC-1 and UMSCC-47; supplementary figures 2 and 3), confirming that these effects of panobinostat treatment are not specific to FaDu cells.
Panobinostat, like many HDACi, results in a rapid and significant increase in p21
Waf1/Cip1 protein expression 24 . Furthermore, p21
Waf1/Cip1 overexpression inhibits the transcription of PLK1, mediated by the cell cycle-dependent element (CDE) and cell cycle genes homology region (CHR) within the Plk1 promoter 25, 26 . Cyclin B1 expression has also been shown to be regulated by p21
Waf1/Cip127 . We therefore hypothesized that the loss of cell cycle dependent PLK1 and Cyclin B1 expression in panobinostat treated cells was due to panobinostatinduced increase in p21
Waf1/Cip1 expression prior to mitotic entry. p21
Waf1/Cip1 RNA and protein levels following panobinostat treatment of synchronised cells were analysed as before (figure 6). A dramatic increase in p21
Waf1/Cip1 mRNA and protein expression was observed in panobinostat treated cells that was not observed in the control population. The timing of the upregulation of p21
Waf1/Cip1 was of particular significance. p21
Waf1/Cip1 mRNA was double that observed in control cells by 2 hours and increased 10-fold by 4 h. More importantly, p21
Waf1/Cip1 protein increased minimally by 4 h post release (1.2-fold) and significantly (3-fold) at 8 h post release in panobinostat treated cells whereas no increase in p21 Waf1/Cip1 protein was observed in control treated cells ( figure 6C ). p21 Waf1/Cip1 protein binds to the transcriptional activator E2F1 and prevents E2F-dependent activation of the PLK1 promoter 26 . In addition, the PLK1 and Cyclin B1 promoters are positively regulated by E2F family members 28, 29 . Therefore, we determined the effect of panobinostat treatment on the expression of E2F family members in synchronised cells ( figure 7A ). mRNA expression of all E2Fs tested is reduced following treatment with panobinostat, with the greatest effect on E2F3, which was repressed at least 2-fold compared to control cells at 4 h post release. However, no significant reduction in the protein levels of E2F1, E2F2 and E2F3 were observed by western blot (data not shown). To explore the possibility that treatment with panobinostat results in reduced association of the activating E2F family members, E2Fs 1, 2 and 3, with the PLK1 and Cyclin B1 promoters and therefore loss of G 2 -specific activation of PLK1 and Cyclin B1 expression, we measured association of these proteins with the endogenous PLK1 and Cyclin B1 promoters by ChIP assay. Treatment of cells with panobinostat for 6 h caused a dramatic reduction in the association of E2F1 with both the PLK1 and Cyclin B1 promoters (figures 7B and C). In contrast, E2F2 and E2F3 were detected at both promoters at similar levels in control and panobinostat treated cells.
Discussion
We and others have shown that panobinostat results in a cell cycle arrest at G 2 /M [20] [21] [22] 30 . The use of synchronised cell populations has now enabled us to show definitively that the cells progress through S phase with normal kinetics, followed by a significant delay at the G 2 checkpoint and decreased mitotic entry. Cells that eventually enter mitosis display significant abnormalities such as misaligned and lagging chromosomes. Live cell imaging confirms that successful completion of mitosis in the presence of panobinostat is a rare event. The experiments presented here have been carried out primarily in FaDu cells, but the G 2 arrest and changes in Plk1 and Cyclin B1 expression following panobinostat treatment of synchronised cells have been confirmed in UMSCC-1 and UMSCC-47 ( 20 and supplementary figures 1, 2 and 3) , demonstrating that the G 2 arrest caused by panobinostat treatment observed in our studies is not specific to a particular cell line. It is interesting to note that FaDu and UMSCC-1 cells are HPV negative while UMSCC-47 cells are HPV positive, indicating that the HPV status of the cells used in these experiment does not affect the response to panobinostat.
It should be noted that our data are in contrast to a study by Pettazzoni et al. 21 , which demonstrates an increase in histone H3 acetylation and phosphorylation at serine 10 following treatment with panobinostat. While we did not specifically look at acetylation of histone H3, the study by Pettazzoni et al. indicates that phosphorylation at serine 10 is not affected by increased acetylation, indicating that increased acetylation is not responsible for the loss of histone H3 phosphorylation in our study (figure 1). Pettazzoni et al. also show an increase in mitotic cells, normal Cyclin B1 protein expression and a subtle decrease in Cdc2 phosphorylation at threonine 14 and tyrosine 15 in an asynchronous population following treatment with panobinostat. From these experiments, it was concluded that panobinostat treatment pushes cells into mitosis, increasing the proportion of cells at G 2 /M, followed by subsequent mitotic failure resulting in cell death. These experiments were performed in prostate cancer cells (LNCaP, DU145 and PC3) and while this difference alone could account for the differential response to panobinostat treatment, all of the experiments reported by Pettazzoni et al. were also performed at low concentrations of panobinostat (10 nM). Indeed, a study by Brazelle et al. 22 in which various non-small cell lung cancer cells were treated with 40 nM panobinostat documented a G2/M arrest but also noted a subtle increase in the phosphorylation of histone H3 at serine 10 and an increase in multinucleated cells that indicates mitotic catastrophe. It is possible that different cell types respond differently to panobinostat exposure with either arrest of the cells prior to mitotic entry (our study), or mitotic catastrophe due to inappropriate mitotic entry 21, 22 , or that different effects on the cell cycle may be caused by different concentrations of drug used. In order to address this question, we have carried out an experiment in which synchronized FaDu cells were treated with 25 nM panobinostat and progression through the cell cycle compared to cells in excipient control or 100 nM panobinostat (supplementary figure 4) . These experiments show that in agreement with the experiments presented in Figures 1-3 , cells in excipient control pass through the S, G2 and mitotic checkpoints normally and cells treated with 100 nM panobinostat are almost completely arrested at the G2/M peak of the flow analysis with minimal slippage through mitosis and into G1. However, cells released into medium containing 25 nM panobinostat pass through mitosis more frequently and by 12 hours post release, an almost 100% increase in G1 cells is observed when compared to cells treated with 100 nM panobinostat (12.39% G1 with 100 nM panobinostat compared to 23.12% G1 cells with 25 nM panobinostat). It will be interesting to determine whether other cells derived from HNSCC behave in the same way as prostate and lung cancer cells at low dose panobinostat and rather than arresting at G2, pass through this checkpoint and into mitosis with catastrophic consequences. The potential differential effects with varying panobinostat concentration are likely to be very important in the clinical use of panobinostat and should be taken into consideration when designing new clinical trials. During a phase I clinical trial in which intravenous panobinostat was administered, it was demonstrated that the half-life of panobinostat is in the order of 10-14 hours and serum concentrations of 400-700 nM are achievable at doses that are well tolerated 31 . These data indicate that the experiments carried out in this study have relevance to the clinical use of panobinostat and that the dose administered needs to be carefully assessed for optimal performance of this drug in treating different malignancies.
In agreement with our study, cells treated with various HDACi (although not panobinostat) were delayed at the G2 checkpoint and progressed slowly through mitosis 32 . In this study, cells arrested for an extended period in prometaphase with infrequent progression to metaphase and anaphase. Mitotic defects similar to those observed in our study were also demonstrated along with a significant increase in transit time through mitosis. Interestingly, combined treatment of cells with the HDACi suberohydroxamic acid (SBHA) and nocodazole, to inactivate the spindle assembly checkpoint, resulted in delayed mitotic entry followed by mitotic exit with similar kinetics to untreated cells. This provides evidence that SBHA treated cells override the spindle assembly checkpoint and exit mitosis with aberrant chromosome segregation.
It is well documented that p21 Waf1/Cip1 protein expression is induced by numerous HDACi (reviewed by 33 ). The activation of p21
Waf1/Cip1 by various HDACi has been demonstrated in p53 null or mutant cells such as the FaDu cells used in this study, which have a homozygous mutation in p53 at codon 248 that results in an arginine to leucine substitution rendering p53 incapable of activating transcription from a variety of promoters 34, 35 . The activation of p21
Waf1/Cip1 by HDACi in cells with mutated or null p53 protein has been studied and in this context activation of p21
Waf1/Cip1 requires acetylation of H2A.X at the p21 promoter 36 . p21
Waf1/Cip1 has pleiotropic effects on cell cycle progression, mediated primarily by association with and inhibition of Cyclin dependent kinases (CDKs) leading to G 1 , S or G 2 -specific growth arrest. The kinetics of the increase in p21
Waf1/Cip1 protein expression observed in this study are in agreement with that seen by Maiso et al. who document an increase in p21
Waf1/Cip1 protein 3 h following treatment with 100 nM panobinostat 24 . We speculated that this dramatic increase in p21
Waf1/Cip1 protein levels, which coincides with mitotic entry in our experimental system results in the repression of other p21
Waf1/Cip1 regulated genes that are essential for mitotic entry and exit, although why a co-incident G 1 arrest is not observed in asynchronously growing cells from HNSCC treated with panobinostat has not been resolved. It is worth noting that p21
Waf1/Cip1 can inactivate proliferating cell nuclear antigen (PCNA) thereby inhibiting PCNAdependent DNA replication 37 . However, DNA replication appears to progress normally in the presence of panobinostat leading us to conclude that this does not contribute to the growth arrest caused by panobinostat in our experiments.
We attribute the panobinostat-mediated G 2 delay and downstream mitotic defects to aberrant Plk1 and Cyclin B1 expression since reduction of Plk1 expression by RNA interference produces similar mitotic and cytokinesis defects, and Cyclin B1 knockdown causes a G 2 delay and slower mitotic transition with similar abnormalities to those observed in this study 38, 39 . It has been demonstrated that both the PLK1 and Cyclin B1 promoters are repressed by the over expression of p21 Waf1/Cip1 [25] [26] [27] . A role for the E2F family of transcription factors in the positive regulation of PLK1 expression has also been reported. E2Fs 1, 2 and 3 act directly on the PLK1 promoter to stimulate transcription activation 28 . Furthermore, p21
Waf1/Cip1 has been shown to control the activity of E2F1 and prevent E2F1-dependent activation of promoters that contain E2F binding sites. This is at least in part independent of Retinoblastoma (Rb) protein function and is reported to be through a direct interaction between p21
Waf1/Cip1 and E2F1 40 . We have assessed the occupancy of the endogenous Plk1 and Cyclin B1 promoters by E2Fs 1, 2 and 3 by ChIP assay and show a dramatic and significant decrease in E2F1 protein associated with both of these promoters. This was somewhat surprising since the mRNA expression of E2F1 is least affected by treatment with panobinostat, however, the PLK1 promoter at least is most responsive to E2F1 28 and small changes in protein levels or activity could have dramatic effects on the expression of downstream activated genes. Nonetheless, these findings support our hypothesis that panobinostat-induced p21
Waf1/Cip1 protein expression results in the E2F1 dependent repression of G 2 -specific genes. Whether this is regulated by post-translational modification including acetylation Waf1/Cip1 mRNA levels normalised to 0 hour time point and are shown as the mean and standard deviation of three independent experiments. (B) 60 mg protein from each extract was separated by SDS-PAGE on two separate gels runs using identical conditions and p21
Waf1/Cip1 (upper panel) and b-actin (lower panel) protein levels were assessed by Western blot. Full-length digital images of these western blots can be viewed in the supplementary information (supplementary figure 5) .
(C) p21
Waf1/Cip1 protein levels from three independent experiments were quantified using ImageGauge v4.21 software and normalised to b-actin levels from the same experiment. The data shown represent the mean and standard deviation. , changes in sub-cellular localization of E2F1, or direct interaction of p21
Waf1/Cip1 and E2F1 following panobinostat treatment are hypotheses we are currently exploring.
Our study provides evidence that panobinostat treatment causes a G 2 delay and abnormal mitotic progression through p21
Waf1/Cip1 -mediated suppression of E2F1 activation of Cyclin B1 and PLK1 expression, which are required for passage through the G 2 checkpoint and normal mitotic transition. Our findings will inform future clinical studies designed to explore how panobinostat might be used in combination with other therapies to improve outcomes in patients with epithelial tumours, for example, through its sequential delivery with other mitosis blocking agents such as taxanes. Given that there is now considerable interest in exploring how epigenetic priming may make cancer cells more sensitive to radiotherapy, there is a compelling case for adding panobinostat to the list of HDAC inhibitors currently under evaluation as potential modulators of radiation sensitivity [41] [42] [43] . We are currently addressing these possibilities to optimise the use of panobinostat in future pre-clinical trials designed to determine whether these combinations would be more effective and less toxic than current regimens.
Methods
Cell culture. FaDu cells (ATCC #HTB-43), are an HPV negative cell line derived from a squamous cell carcinoma of the hypopharynx, were cultured at 37uC, 5% CO 2 in RPMI 1640, containing 10% fetal bovine serum and 1 mM sodium pyruvate. UMSCC-1 cells originate from a tumour from the floor of the mouth in a male patient and are HPV negative. UMSCC-47 cells are derived from a tumour of the lateral tongue in a male patient and are HPV16 positive. Both of these cell lines were approved and cultured as previously described 23, 44 . Cells are routinely tested for mycoplasma infection using a MycoAlert kit (Lonza).
Panobinostat. Panobinostat (LBH589; obtained from Peter Atadja, Novartis) was dissolved in d5W to 4.6 mM, the stock was then diluted to 100 nM in culture medium. Excipient control was prepared at the same d5W dilution.
Cell cycle synchronisation. 2 mM thymidine was added to 50% confluent cells, which were incubated for 15 h. Cells were then reseeded at 2 3 10 6 cells/10 cm plate and left to recover for 12 h. 2 mM thymidine was added again and the cells were incubated for 14 h. Cells were either harvested immediately (0 h) or released in medium containing panobinostat or D5W alone (control) and harvested at the indicated times.
Flow cytometry. Cells were trypsinised and fixed in 1 ml of ice cold 70% ethanol. Cells were then washed in 1% BSA/PBS, and incubated for 30 min in BSA/PBS containing 50 mg/ml propidium iodide and 20 mg/ml RNase A. Samples were analysed using a FACSCanto II (Becton Dickinson) flow cytometer equipped with a 488 nm laser. Emission was detected using a 585/42 nm band pass filter. Data were analysed using ModFit LT 3.0 software (Verity Software House).
For immunofluorescent staining of phosphorylated histone H3, cells were fixed with 1% formaldehyde in PBS before fixing in ethanol. Cells were resuspended in 1% BSA/PBS containing with Alexa 488-conjugated anti-phospho-histone H3 (Ser10) antibody (Cell Signaling 9708) and incubated for 1 h before staining with propidium iodide. Cells were analysed as described above with the additional measurement of fluorescence emission using 530/30 nm band pass filter.
Chromosome analysis and immunofluorescence. Cells were synchronised and released into culture medium, followed by standard hypotonic treatment and fixation in methanol/acetic acid. For immunofluorescence, panobinostat treated and control cells were grown on glass coverslips and fixed in ice cold methanol for 10 min. Cells were then incubated with 5% goat serum followed by incubation with mouse anti atubulin (DM1A, Sigma; 151000) and detection with anti mouse Alexa-488 (Invitrogen; 151000). The cells were counterstained with DAPI and imaged with an Axiovert 200 microscope (Zeiss) with an oil immersion lens (603, NA 1.35).
Live cell imaging. Time-lapse microscopy was performed with a 203/0.5 NA phase contrast objective on an inverted microscope (NIKON TE2000-E) at 37uC and 5% CO 2 . Red LED illumination (CoolLED) and a CCD camera (Andor iXon), controlled by Micro-Manager software were used to acquire one image every 2 min 45 . RNA extraction. Total RNA was isolated using TRIzol (Invitrogen). RNA was quantified using a Nanodrop 2000 and quality was confirmed using an Agilent Bioanalyzer and Agilent RNA 6000 Nanochips. All had RNA Integrity Numbers $9.2.
Quantitative real time PCR. qRT-PCR was performed using the Taqman RNA-to-C T 1-Step Kit (Applied Biosystems) and Gene Expression Assays; CDKN1A (p21) (Hs00355782_m1), PLK1 (Hs00153444), CCNB1 (Cyclin B1) (Hs01030097_m1) and GAPDH (Hs99999905_m1). Individual reactions were set up in triplicate from a master mix (32 ml Taqman 23 RT-PCR mix, 3.2 ml RNA (100 ng/ml), 3.2 ml primers (18 mM), 1.6 ml enzyme, 24 ml water). qRT-PCR measurements were performed on a StepOnePlus RT-PCR instrument (Applied Biosystems), using the following program: 48uC for 15 min, 95uC for 10 min and 40 cycles of 95uC for 15 s, 60uC for 1 min. The comparative threshold (C T ) was determined for each gene as the average of three separate experiments.
Normalized values (DC T ) were calculated by subtracting the C T for GAPDH from the C T of each gene. DDC T values for each time point/condition was generated by subtracting the DC T for each time sample from the DC T of the 0 hour sample for each experiment. The power (2, DDC T ) was used to determine the fold change of the gene of interest in each sample relative to the 0 hour sample for each experiment.
Protein sample preparation and quantification. Cells were lysed in ice cold RIPA buffer (1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 2 mM EDTA, 25 mM TrisHCl, pH 7.5 containing 13 Complete protease inhibitors (Roche)). The genomic DNA was sheared by passing the lysate 33 through a 21-gauge needle and lysates cleared by high-speed centrifugation at 4uC. Protein concentration was determined by BCA assay (Pierce).
Western blotting. Membranes were probed with anti-Plk1 antibody (Abcam Ab70697, 151000), p21
Waf1/Cip1 (Dako SX118, 151000), Cyclin B1 (Santa Cruz H-433, 151000) or H2AX (Bethyl A300-081, 151000) and either anti-mouse or anti-rabbit secondary antibody conjugated to HRP (Jackson Laboratories. 1510,000). Detection was performed using Supersignal Dura (ThermoFisher Scientific) and images captured on a Fujifilm LAS3000 digital detection system. Protein levels were quantified using ImageGauge.
Chromatin immunoprecipitation. Cells were treated with 100 nM panobinostat for 6 h before crosslinking with 1% formaldehyde for 30 min. 120 mM Glycine (final concentration) was added for 5 min before washing with PBS. 300 ml lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS and 13 protease inhibitor cocktail) was added and the cells harvested by scraping. Samples were sonicated and centrifuged at 14,000 rpm, 4uC. Supernatants were diluted 10-fold in ChIP dilution buffer (16.7 mM Tris-HCl, pH 8.0, 0.01% SDS, 1.1% Trition-X-100, 1.2 mM EDTA, 167 mM NaCl, 13 protease inhibitor cocktail) and to 1 ml of each sample, 10 ml 50% slurry Protein G magnetic sepharose beads (Invitrogen) and 2 mg of antibody (FLAG M2 (Sigma, F1804), E2F1 (Abcam, ab94888), E2F2 (Abcam, ab65222) or E2F3 (Abcam, ab74180)) was added. Following incubation at 4uC for 2 h with nutation, beads were washed in low salt buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 2 mM EDTA, 0.5% Triton-X-100), high salt buffer (20 mM Tris-HCl, pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% NP40, 1% Na-deoxycholate), and TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). 100 ml elution buffer (1% SDS, 100 mM NaHCO 3 ) was then added to each sample and incubated for 30 min. NaCl concentration was made up to 200 mM and the samples incubated overnight at 65uC. 10 mM EDTA, 40 mM Tris-HCl, pH 8.0 (final concentration) and RNase A (0.25 mg/ml) were added to each sample followed by incubation at 37uC for 1 h. Proteinase K (50 mg/ml final) was added and the samples incubated at 50uC for 1 h. The DNA was extracted with phenol-chloroform and ethanol precipitated. Pellets were resuspended in 20 ml water.
For qRT-PCR analysis a 10-fold serial dilution of input samples was created and 1 ml of each sample added to 24 ml Brilliant II SyBr Green mastermix (Agilent Technologies) containing 10 pmol of each primer for amplification of the PLK1 promoter (forward: 59-GGTTTGGTTTCCCAGGCTAG-39, reverse: 59-GCTG-GGAACGTTACAAAAGC-39) 28 or the Cyclin B1 promoter (forward: 59-CGAT-CGCCCTGGAAACGCATTC-39, reverse 59-CCAGCAGCCACCAACAG-CCGTTC-39) 46 . DNA was amplified by incubation at 95uC for 10 min followed by 40 cycles of 95uC for 30 s, 57uC for 30 s and 72uC for 1 min. Ct values for each sample were calculated at a constant threshold and expressed as fold change over negative control.
